Get Instant Stock Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
SOPHiA GENETICS SA (NASDAQ : SOPH) Stock
MWN-AI** Summary
SOPHiA GENETICS SA (NASDAQ: SOPH) is a pioneering biotechnology company headquartered in San Francisco, California, specializing in data-driven medicine. The company is renowned for its advanced analytics platform, SOPHiA DDM™, which harnesses the power of artificial intelligence to interpret and classify genomic data. This platform empowers healthcare institutions to make informed decisions based on comprehensive genomic insights, primarily focusing on oncology, hereditary disorders, and infectious diseases.
Founded in 2011 in Switzerland, SOPHiA GENETICS aims to democratize data-driven medicine by making genomic information accessible and actionable for clinicians and researchers. The company's innovative solutions are particularly beneficial in the identification and treatment of cancer, where understanding the genetic makeup of tumors can significantly improve therapeutic outcomes. SOPHiA’s technology is designed to streamline the workflow of genomic analysis, making it faster and more cost-effective while facilitating collaboration among healthcare providers worldwide.
Over the years, SOPHiA GENETICS has established partnerships with various hospitals, laboratories, and research institutions, expanding its reach and enhancing the capabilities of its platform. The company went public in 2021, providing it with additional capital to invest in research and development and further extend its market presence.
As of October 2023, SOPHiA GENETICS continues to innovate and refine its platform in response to the evolving demands of precision medicine. The company is focused on expanding its product offerings and enhancing customer engagement. Despite facing competition in the rapidly growing field of genomic technology, SOPHiA GENETICS remains a key player with a strong vision for improving patient care through data-driven insights, positioning itself as a critical player in transforming healthcare through genomic information.
MWN-AI** Analysis
As of October 2023, SOPHiA GENETICS SA (NASDAQ: SOPH) presents an intriguing investment opportunity within the rapidly evolving landscape of genomic data analytics and personalized medicine. The company specializes in providing a cloud-based platform that enables healthcare providers to leverage data-driven insights to enhance patient care, particularly in oncology and rare diseases.
Analyzing the recent market performance of SOPH, several factors suggest a cautiously optimistic outlook. The demand for genomic sequencing and personalized medicine continues to escalate, driven by advancements in technology and a growing emphasis on precision health. SOPHiA's innovative platform, which integrates artificial intelligence with genomic data, positions it favorably to capitalize on these trends. Furthermore, the company's partnerships with key players in the healthcare sector enhance its credibility and broaden its reach.
However, potential investors must be mindful of the competitive landscape. The genomic data analytics market is increasingly crowded, with several established players and new entrants vying for market share. SOPHiA's ability to differentiate itself through unique offerings and superior technology will be critical in maintaining its competitive edge.
Additionally, the company's financial metrics should be scrutinized. Despite its strong growth potential, SOPH has yet to achieve profitability, which is a consideration for risk-averse investors. Monitoring its revenue growth, customer acquisition costs, and any updates on regulatory approvals will be essential in evaluating its performance.
In conclusion, SOPHiA GENETICS SA offers an attractive investment proposition within a dynamic industry. Investors should closely watch its growth trajectory, competitive positioning, and financial health. Given the volatility often associated with biotech investments, a long-term perspective coupled with diligent research may provide the best opportunity for capitalizing on potential growth within this sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
Quote
| Last: | $6.83 |
|---|---|
| Change Percent: | -8.45% |
| Open: | $7.53 |
| Close: | $6.83 |
| High: | $7.65 |
| Low: | $6.79 |
| Volume: | 1,411,879 |
| Last Trade Date Time: | 11/19/2026 03:45:49 pm |
Stock Data
| Market Cap: | $320,789,141 |
|---|---|
| Float: | 55,476,472 |
| Insiders Ownership: | N/A |
| Institutions: | 27 |
| Short Percent: | N/A |
| Industry: | Healthcare Providers & Services |
| Sector: | Healthcare |
| Website: | https://www.sophiagenetics.com |
| Country: | CH |
| City: | Rolle |
Chart & Financials
Recent News Releases
Subscribe to Our Newsletter
FAQ**
What recent developments or partnerships has SOPHiA GENETICS SA SOPH announced that could impact its growth trajectory in the genetic analytics market?
How does SOPHiA GENETICS SA SOPH differentiate its technology from competitors in the field of genomic data analysis?
What are the key financial metrics investors should consider when evaluating SOPHiA GENETICS SA SOPH for potential investment?
How does SOPHiA GENETICS SA SOPH plan to expand its market presence internationally, and what challenges could it face in doing so?
**MWN-AI FAQ is based on asking OpenAI questions about SOPHiA GENETICS SA (NASDAQ: SOPH).


